全文获取类型
收费全文 | 3364篇 |
免费 | 128篇 |
国内免费 | 725篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 54篇 |
妇产科学 | 6篇 |
基础医学 | 170篇 |
口腔科学 | 5篇 |
临床医学 | 274篇 |
内科学 | 2123篇 |
皮肤病学 | 8篇 |
神经病学 | 11篇 |
特种医学 | 41篇 |
外科学 | 277篇 |
综合类 | 408篇 |
预防医学 | 113篇 |
眼科学 | 1篇 |
药学 | 264篇 |
2篇 | |
中国医学 | 429篇 |
肿瘤学 | 28篇 |
出版年
2024年 | 7篇 |
2023年 | 77篇 |
2022年 | 182篇 |
2021年 | 187篇 |
2020年 | 194篇 |
2019年 | 158篇 |
2018年 | 136篇 |
2017年 | 106篇 |
2016年 | 157篇 |
2015年 | 146篇 |
2014年 | 366篇 |
2013年 | 291篇 |
2012年 | 245篇 |
2011年 | 289篇 |
2010年 | 227篇 |
2009年 | 206篇 |
2008年 | 223篇 |
2007年 | 220篇 |
2006年 | 153篇 |
2005年 | 127篇 |
2004年 | 64篇 |
2003年 | 60篇 |
2002年 | 42篇 |
2001年 | 42篇 |
2000年 | 31篇 |
1999年 | 40篇 |
1998年 | 26篇 |
1997年 | 22篇 |
1996年 | 11篇 |
1995年 | 18篇 |
1994年 | 18篇 |
1993年 | 15篇 |
1992年 | 19篇 |
1991年 | 10篇 |
1990年 | 11篇 |
1989年 | 16篇 |
1988年 | 9篇 |
1987年 | 13篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1971年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有4217条查询结果,搜索用时 0 毫秒
31.
Primary sclerosing cholangitis is a disease affecting around 0.006–0.016% of the population. Of these, around 75% have concomitant inflammatory bowel disease (IBD) according to the most recent epidemiological studies. Several theories have been proposed regarding the pathogenesis of primary sclerosing cholangitis (PSC). These include changes in the function of cholangiocytes, effects of the gut microbiome, association with specific human leukocyte antigen haplotypes and dysregulation of the immune system. However, these do not explain the observed association with IBD. Moreover, there are considerable differences in the frequency and outcomes between patients with PSC and ulcerative colitis compared with PSC and Crohn’s disease. The aim of this review is to appraise the most recent studies that have contributed to the epidemiology, advances in the pathophysiology, and characterization of important clinical aspects of the association of PSC and IBD. 相似文献
32.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
33.
34.
35.
36.
《Best Practice & Research: Clinical Gastroenterology》2014,28(3):387-397
Inflammatory bowel disease, consisting of Crohn's disease and ulcerative colitis, is a chronic inflammatory disease of the gut, which arises through an excessive immune response to the normal gut flora in a genetically susceptible host. The disease affects predominantly young adults and due to its chronic and relapsing nature gives rise to a high disease burden both financially, physically and psychologically. Current therapy still cannot prevent the need for surgical intervention in more than half of IBD patients. Consequently, advances in IBD therapy are of high importance. Recently, several new forms of targeted therapy have been introduced, which should improve surgery-free prognosis of IBD patients. Recent identification of genetic risk variants for IBD has led to new insights into the biological mechanisms of the disease, which will, in the future, lead to new targeted therapy. In the meantime repositioning of drugs from biologically similar diseases towards IBD might lead to new IBD therapies. 相似文献
37.
38.
Stephen J Halpin P John Hamlin Daniel P Gree Lisa Warren Alexander C Ford 《World journal of gastroenterology : WJG》2013,19(7):1091-1097
AIM:To suggest infliximab(IFX) is effective for acute severe ulcerative colitis,from real-life clinical practice.METHODS:All patients receiving IFX for the treatment of acute severe ulcerative colitis in a single centre were included.Data were extracted from clinical records in order to assess response to IFX therapy.The primary endpoint was colectomy-free survival,and secondary outcomes included glucocorticosteroid-free remission and safety,which was evaluated by recording deaths and adverse events.Demographic and clinical characteristics of those who underwent colectomy and those who were colectomy-free,both at discharge from their index admission,and during follow-up after an initial response to IFX were compared.RESULTS:Forty-four patients(16 females,mean age 36 years) received IFX between May 2006 and January 2012 for acute severe ulcerative colitis.The median duration of follow-up post-first infusion was 396 d(interquartile range = 173-828 d).There were 21(47.7%) patients with < 1 year of follow-up,10(22.7%) with 1 years to 2 years of follow-up,and 13(29.5%) with > 2 years of follow-up post-first infusion of IFX.Overall,35(79.5%) responded to IFX,avoiding colectomy during their index admission,29(65.9%) were colectomyfree at last point of follow-up(median follow-up 396 d),and 25(56.8%) were in glucocorticosteroid-free remission at end of follow-up.There was one death from post-operative sepsis,20 d after a single IFX infusion.Colectomy rates were generally lower among those "bridging" to thiopurine.Of 18 patients "bridged" to thiopurine therapy,17(94.4%) were colectomyfree,and 15(83.3%) were in glucocorticosteroid-free remission at study end.No predictors of response were identified.CONCLUSION:IFX is effective for acute severe ulcerative colitis in real-life clinical practice.Two-thirds of patients avoided colectomy,and more than 50% were in glucocorticosteroid-free remission. 相似文献
39.
The presentations at Digestive Disease Week 2013 emphasized treatment safety. Anti-tumor necrosis factor (TNF) agents and thiopurines are reasonably safe in breastfeeding and pregnancy. Several studies indicate that controlling the risk of tuberculosis when anti-TNF agents are planned presents several problems, both in the initial diagnosis of latent tuberculosis and in subsequent patient follow-up, given that cases of tuberculosis continue to occur, despite recommendations. Thiopurines increase the risk of lymphoma, but there is no residual risk when these drugs are withdrawn. Despite increasing knowledge of the risks and recommendations on how to avoid them, there remain considerable shortfalls in the application of preventive measures and, more specifically, in vaccinations. Infliximab and cyclosporin produce similar results when used to treat severe outbreaks of ulcerative colitis. Thromboembolism prevention continues to be deficient, and the barriers to effective prevention concern not only physicians but can also involve nursing staff, for example. There is still a wide margin for improvement in safety. New drugs under study (vedolizumab, golimumab) have not shown any hitherto unknown signs of significant toxicity. 相似文献
40.
João Carlos Silva Carlos Fernandes Jaime Rodrigues Sónia Fernandes Ana Ponte Adélia Rodrigues 《Scandinavian journal of gastroenterology》2020,55(10):1157-1162
Abstract